CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Background: The therapeutic efficacy of chimeric antigen receptor (CAR) T-cells targeting CD19 has been illustrated in the treatment of diffuse large B-cell lymphoma (DLBCL). However, there is a 21–35% relapse rate after anti-CD19 CAR T-cell induced remission. In addition, CAR T-cell therapy has sev...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Oncol
Glavni autori: Tu, Sanfang, Zhou, Xuan, Guo, Zhenling, Huang, Rui, Yue, Chunyan, He, Yanjie, Li, Meifang, Chen, Yiran, Liu, YuChen, Chang, Lung-ji, Li, Yuhua
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2019
Teme:
Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6904344/
https://ncbi.nlm.nih.gov/pubmed/31867275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01350
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items